DSIP (delta sleep-inducing peptide)
Cognitive · Neuropeptide
Tier C+
Bottom line
Read Off Label grades DSIP (delta sleep-inducing peptide) as C+ (5.7/10) based on weak evidence, variable benefit magnitude, and a low-risk safety profile.
First characterized Monnier 1977.
Studied, labeled, or reported-use context: 100-500 mcg subQ at night (anecdotal) — Research peptide; PCAC voted 6-7 (one abstention) against adding emideltide/DSIP to the 503A bulks list — the only one of the seven rejected (Jul 23-24, 2026) — advisory only, not an FDA approval or a final compounding decision; not individualized guidance.
What the evidence says
First characterized Monnier 1977. Despite the name, not reliably sleep-inducing in controlled studies. Popular in peptide community for sleep/recovery; evidence is thin. Short plasma half-life. The FDA Pharmacy Compounding Advisory Committee (PCAC) met Jul 23-24, 2026 and voted on seven peptides for the 503A bulk drug substances list. Committee votes are advisory: the FDA is not bound by them, adding a substance to the 503A list would follow notice-and-comment rulemaking, and inclusion would permit compounding — it would not constitute FDA approval, an efficacy finding, or a safety determination. FDA's own review staff had recommended against the four Jul 23 peptides, citing poor characterization, weak human efficacy and safety evidence, and unassessed immunogenicity; press coverage also noted committee members' financial ties to the peptide industry. The underlying human evidence base for these compounds is unchanged by the vote. On this compound the committee voted 6-7 (one abstention) against adding emideltide/DSIP to the 503A bulks list — the only one of the seven rejected.
Mechanism
Nonapeptide isolated from rabbit brain dialysate during delta sleep; proposed sleep modulatory and stress-protective effects; mechanism unclear
Studied, labeled, or reported dose & route
100-500 mcg subQ at night (anecdotal)
This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.
Citations
A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.
Common questions
- What does the evidence show about DSIP (delta sleep-inducing peptide)'s effects?
- Read Off Label rates the evidence for DSIP (delta sleep-inducing peptide) as Weak and the benefit magnitude as variable, producing an overall grade of C+ (5.7/10). First characterized Monnier 1977.
- What safety findings are reported for DSIP (delta sleep-inducing peptide)?
- DSIP (delta sleep-inducing peptide) has a low risk profile in the database. Low (limited data) Legal status: Research peptide; PCAC voted 6-7 (one abstention) against adding emideltide/DSIP to the 503A bulks list — the only one of the seven rejected (Jul 23-24, 2026) — advisory only, not an FDA approval or a final compounding decision.
- What doses or routes are reported for DSIP (delta sleep-inducing peptide)?
- 100-500 mcg subQ at night (anecdotal) This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
- How does DSIP (delta sleep-inducing peptide) work?
- Nonapeptide isolated from rabbit brain dialysate during delta sleep; proposed sleep modulatory and stress-protective effects; mechanism unclear
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.